Co-Diagnostics Engages in High-Level Global Health Discussions During UNGA Week — Co-Diagnostics, Inc. (Co-Dx)

Event summary

Co-Diagnostics' Chief Commercialization Officer Seth Egan will participate in two global health events during the 81st UN General Assembly in New York City on September 23 and 25, 2026.
The company is advancing its molecular diagnostics platform for tuberculosis and respiratory infections, with ongoing clinical studies in India and a pending FDA submission in the U.S.
WHO recently recommended near-point-of-care molecular diagnostics and tongue-swab sampling for tuberculosis testing, aligning with Co-Dx's platform.
Co-Dx submitted a 510(k) premarket notification and CLIA Waiver by Application to the FDA in August 2026 for its Co-Dx™ PCR Flu A/B & RSV test.

The big picture

Co-Diagnostics' participation in high-level UN events underscores the growing emphasis on pandemic preparedness and respiratory disease diagnostics. The company's focus on decentralized testing aligns with global health priorities, particularly as regulatory bodies like the WHO and FDA shape the future of molecular diagnostics. Success in securing regulatory clearances and expanding its platform's applications will be critical for its market positioning.

What we're watching

Regulatory Progress: Whether Co-Diagnostics can secure FDA clearance for its Flu A/B & RSV test and sustain momentum in clinical studies for its tuberculosis test in India.
Market Positioning: How the company leverages WHO's recommendations to differentiate its decentralized testing model in the competitive diagnostics market.
Strategic Partnerships: The extent to which engagements with global health organizations translate into commercial or regulatory advantages.